Commentary on Buss et al.: State endorsement as a driver of vape‐assisted smoking cessation: Interpreting early evidence from Swap to Stop

England's Swap to Stop programme was associated with increased vape assisted quit attempts. Beyond improving access, institutional endorsement may influence risk perceptions and cessation choices. These findings suggest a potential policy driven behavioural shift with important implications for population level cessation support and the implementation of harm‐reduction strategies.

Buss et al. [1] report that the introduction of England's national Swap to Stop programme, which provides free vape starter kits alongside behavioural support, was associated with a sustained 1.5‐percentage‐point increase in the proportion of past‐year smokers using vapes in a quit attempt. Using interrupted time‐series analyses of Smoking Toolkit Study data, the authors estimate that this corresponds to approximately 125 000 additional vape‐assisted quit attempts in the first year. The findings highlight the potential public health benefit of increasing the use of an evidence‐based cessation aid. A further implication may lie not only in improved access to vaping for cessation, but also in the influence of institutional endorsement on cessation method choices under conditions of uncertainty about relative risks.

Substantial evidence suggests that nicotine vaping products can support smoking cessation. A recent Cochrane review concluded that e‐cigarettes increase quit rates relative to nicotine replacement therapy (NRT) [2]. Randomised trials within United Kingdom (UK) Stop Smoking Services have similarly reported higher abstinence rates among participants assigned to vaping than NRT [3], and trials among people experiencing socio‐economic disadvantage have found comparable results [4]. Population‐level analyses have also linked increases in vaping prevalence with improvements in quit success in England [5]. Within this broader evidence base, Buss et al. [1] show that the introduction of a national distribution programme was associated with an increase in vape‐assisted quit attempts. However, the mechanism may involve more than improved access alone.

Perceptions of risk likely play an important role. Harm perceptions of e‐cigarettes relative to combustible cigarettes have worsened in England since 2014, with many smokers now believing vaping to be equally or more harmful than smoking [5]. These perceptions are associated with a lower likelihood of using vaping in quit attempts [6]. Although Buss et al. [1] did not directly measure trust or perceived legitimacy, one possible explanation is that Swap to Stop functions not only as a material intervention, but also as a signal of institutional endorsement. Delivery through National Health Services‐affiliated and community services may increase the perceived credibility of vaping as a cessation method, thereby influencing behavioural choices.

Institutional credibility may also influence how evidence‐based interventions are adopted and communicated within health systems. Research on the implementation of health interventions highlights the importance of organisational context, professional confidence and supportive implementation infrastructure in enabling uptake [7]. In settings where public narratives about vaping remain contested, embedding vaping within a funded national programme may reduce professional uncertainty and increase the likelihood that clinicians recommend it for smoking cessation. The programme may, therefore, operate both as a clinical intervention, by distributing devices and as a symbolic one that communicates institutional approval of vaping as a cessation aid.

Policy signals are known to influence tobacco‐related behaviour. Interrupted time‐series studies of tobacco control policies show that measures such as tax increases, smoke‐free legislation and mass media campaigns often produce rapid behavioural responses [8, 9]. Buss et al. [1] report an immediate step change following the programme's introduction, which they suggest may partly reflect increased public and media attention surrounding the announcement and launch of the Swap to Stop initiative. Such coverage may function as a cue to action by increasing awareness of vaping as a cessation option among smokers who were not directly receiving a starter kit. Unlike many traditional tobacco control measures, Swap to Stop promotes substitution rather than restriction. It operationalises harm reduction within England's national tobacco control strategy [10] and aligns with clinical guidance supporting vaping for smoking cessation [11].

Equity considerations are also relevant. If institutional endorsement acts as a normative signal, it may be particularly important for groups who are uncertain about the legitimacy or safety of vaping. Evidence from behavioural public policy suggests that government endorsement can increase uptake of health interventions among populations experiencing disadvantage by enhancing perceived legitimacy and signalling normative acceptability [12, 13].

Buss et al. [1] provide early evidence that a state‐backed harm‐reduction initiative delivered at scale can shift cessation behaviour in a direction consistent with existing clinical evidence. As with all interrupted time‐series analyses based on repeat cross‐sectional survey data, the findings should be interpreted as evidence of temporal association rather than definitive causation. Nonetheless, in an environment characterised by contested narratives about vaping, the potential signalling role of government policy, and the extent to which institutional endorsement shapes risk perceptions, healthcare professional recommendations and cessation choices, warrants explicit investigation.

DECLARATION OF INTERESTS

None.

DATA AVAILABILITY STATEMENT

No new data were generated or analysed in support of this commentary.